ArticlePloS one2026
Anti-inflammatory and immunomodulatory potential of lignans from Artemisia cina: Integrated quantum, docking, and cytokine expression studies.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantum, docking, and in vitro studies were performed to evaluate the immunomodulatory function of two lignans isolated from Artemisia cina-3-demethoxy-6-O-demethylisoguaiacin (L1) and norisoguaiacin (L2)-through individual molecular docking with cyclooxygenase-2 (COX-2) and their mixture for cytokine assays. The structures of L1 and L2 were optimized using density functional theory with the B3LYP/6-311++G(d,p) method. The optimized structures were then docked into the COX-2 active site, revealing slightly lower binding affinities (ΔG = -7.57 and -7.13 kcal/mol, respectively) compared with naproxen (-8.95 kcal/mol). The interactions of the ligands with Ser530 and Arg120 in the arachidonate-binding site predict a potential COX-2 inhibition through π-donor hydrogen interactions, along with several hydrophobic and π-π interactions. In the in vitro assays, both lignans significantly upregulated the anti-inflammatory cytokines interleukin (IL)-6, IL-4, and IL-13, which are involved in host protection against nematodes. By contrast, the chemokine CXCL8 was downregulated, indicating a reduction in inflammatory signaling. Moreover, the combination of L1 and L2 with lipopolysaccharide showed a synergistic effect, increasing the relative expression of IL-13 (212.8-fold), highlighting their immunomodulatory activity. These findings from in silico and in vitro assays suggest that the lignans could have potential anti-inflammatory effects, but direct evidence of COX-2 enzymatic inhibition is still lacking. Further in vivo studies are warranted to validate their therapeutic potential. Further in vivo studies are warranted to validate their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.